Changes to This Summary (08�/�02�/�2011)
Recurrent or Persistent Ovarian Epithelial Cancer Treatment
Added Rustin et al. as reference 2.
Added text to state that monitoring CA 125 levels in follow-up may play a role in identifying appropriate candidates for secondary cytoreduction, although this strategy awaits confirmation with a randomized trial.
Revised Table 7 title to read Regimens Used in First Relapse. Added PLD plus trabectedin to list of regimens used in first relapse. Added Monk et al. as reference 4.
Added text to state that in a phase III trial, carboplatin plus PLD (CD) was compared to carboplatin plus paclitaxel (CP) in patients with platinum-sensitive recurrence and a primary endpoint was progression-free survival (PFS) with a median PFS for the CD arm of 11.3 months versus 9.4 months for the CP arm (cited Pujade-Lauraine et al. as reference 13 and level of evidence 1iiDiii).